A Clostridium difficile infection (CDI) stewardship initiative improves adherence to practice guidelines for management of CDI

Infection Control and Hospital Epidemiology

Volumn 34, Issue 11, 2013, Pages 1222-1224

  Jury, Lucy A ^a   Tomas, Myreen ^b   Kundrapu, Sirisha ^b   Sitzlar, Brett ^a   Donskey, Curtis J ^a  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DEHYDROGENASE; METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; EARLY INTERVENTION; ENZYME IMMUNOASSAY; FOLLOW UP; HEALTH PROGRAM; HUMAN; INAPPROPRIATE PRESCRIBING; MEDICAL RECORD REVIEW; NURSE PRACTITIONER; PHYSICIAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; TIME TO TREATMENT;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GUIDELINE ADHERENCE; HUMANS; METRONIDAZOLE; TIME FACTORS; TIME-TO-TREATMENT;

EID: 84885461731     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/673459     Document Type: Article

References (9)

1. Le F, Arora V, Shah DN, Salazar M, Palmer HR, Garey KW. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy 2012; 32: 129-134.
2. Byker GL, Dinh MT, Gunaratnam NT, Robinson EA, Shehab TM, Malani AN. Management of Clostridium difficile infection: survey of practices and compliance with national guidelines among primary care physicians Infect Control Hosp Epidemiol 2009; 30: 397-399.
3. Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gasroenterol 2003; 98: 354-358.
4. Saade E, Deshpande A, Kundrapu S, et al. Appropriateness of empiric therapy in patients with suspected Clostridium difficile infection. Curr Med Res Opin 2013; 29: 985-988.
5. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455.
6. Guerrero DM, Nerandzic MM, Jury LA, Chang S, Jump RL, Donskey CJ. Clostridium difficile infection in a Department of Veterans Affairs long-term care facility. Infect Control Hosp Epidemiol 2011; 32: 513-515.
7. Kundrapu S, Jury LA, Sitzlar B, Sunkesula VCK, Sethi AK, Donskey CJ. Easily modified factors contribute to delays in diagnosis of Clostridium difficile infection: a cohort study and intervention. J Clin Microbiol 2013; 51: 2365-2370.
8. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease Antimicrob Agents Chemother 2008; 52: 2403-2406.
9. Shaughnessy MK, Amundson WH, Kuskowski MA, DeCarolis DD, Johnson JR, Drekonja DM. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection. Infect Control Hosp Epidemiol 2013; 34: 109-116.